Pustular and erythrodermic psoriasis are both dangerous conditions that can pose serious health risks. In the cases they reviewed, Remicade (infliximab), Humira (adalimumab), Enbrel (etanercept) and Stelara (ustekinumab) were used to treat both kinds of psoriasis. If it is an acute, severe flare that requires hospitalization, we would suggest using a fast-acting medication like Remicade or cyclosporine, said Liao. Patients with guttate, pustular, or erythrodermic psoriasis were excluded from the study. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. Cases of acute and chronic leukemia have been reported with postmarketing TNF-blocker use. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis.
Psoriasis patients are not only more likely to have CV risk factors but severe psoriasis may serve as an independent risk factor for CV mortality. The average age at onset for pustular psoriasis is 50 years. Erythrodermic psoriasis may develop gradually or acutely during the course of chronic plaque-type psoriasis, but it may be the first manifestation of psoriasis, even in children. Life-threatening pustular and erythrodermic psoriasis responding to infliximab. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis. Pustular psoriasis is a rare form of psoriasis that may require different approaches to treatment. R. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis.
More severe psoriasis may be treated with phototherapy, or may require systemic therapy. Biologic therapies, including tumor necrosis factor inhibitors, can be effective for severe psoriasis and psoriatic arthritis, but have significant adverse effect profiles and require regular monitoring. Atypical forms include guttate, pustular, erythrodermic, and inverse psoriasis. A severe, acute form (the von Zumbusch variant) can cause life-threatening complications. (Humira), etanercept (Enbrel), and infliximab (Remicade). Moderate-to-Severe Psoriasis that has Failed to Respond to all Currently Approved Therapies for Psoriasis (all TNF Inhibitors, T-Cell Inhibiting Agents, and Acitretin) in Patients who Cannot Receive (a) Methotrexate, due to Excessive ( 10 Drinks per Week) Alcohol Use; and (b) Cyclosporine, due to Either Unmanageable Hypertension or Significantly Reduced Kidney Function. R. Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis. It is also used to treat severe or disabling plaque psoriasis (raised, silvery flaking of the skin). Common side effects of Remicade include headache, stomach pain, nausea, stuffy nose, sinus pain, skin rash, or flushing (warmth, redness, or tingly feeling). Severe liver injury, including acute liver failure and autoimmune hepatitis, has been reported rarely in patients receiving REMICADE see WARNINGS AND PRECAUTIONS.
4 Lisby S, Gniadecki R: Infliximab (Remicade ) for acute, severe pustu-. Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab), Simponi Aria (golimumab intravenous), and Stelara (ustekinumab) brands of targeted immune modulators ( least cost brands of targeted immune modulators ) are less costly to Aetna. Have severe, unstable, life-threatening disease (erythrodermic or pustular psoriasis); or. The investigators concluded that, although the primary endpoint was not met, clinical responses, acute-phase reactant and quality of life improvements were greater with secukinumab versus placebo, suggesting some clinical benefit.